Are Rx-To-OTC Switches Worth The Trouble? Yes They Are, IQVIA Data Shows

 
• By David Ridley

The holy grail of consumer health innovation, Rx-to-OTC switches, are costly and hard to pull off. So, are they worth the effort? An analysis by IQVIA of desloratadine, which was switched in Germany 2020 by Novartis subsidiary, Hexal, shows that they are, with sales of OTC desloratadine products growing 112% between 2019 and 2020. 

Sisyphus metaphor. Man rolling huge concrete ball up hill. Sisyphean work, task.
• Source: Shutterstock

Rx-to-OTC switches are the holy grail of consumer healthcare market innovation and growth. But they are hard work. They require huge investment on the part of firms.

A complicated switch in the US, for example, can cost anywhere in the region of $30m to $50m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography